2型糖尿病的治疗:GLP-1通路

Future Prescriber Pub Date : 2009-01-19 DOI:10.1002/fps.39

Abd A Tahrani MMedSci, MD, MRCP, Milan K Piya MRCP, Anthony H Barnett MD, FRCP

{"title":"2型糖尿病的治疗:GLP-1通路","authors":"Abd A Tahrani MMedSci, MD, MRCP, Milan K Piya MRCP, Anthony H Barnett MD, FRCP","doi":"10.1002/fps.39","DOIUrl":null,"url":null,"abstract":"<p>Type 2 diabetes mellitus (T2DM) is a major challenge to healthcare systems around the world, with an estimated prevalence of 6% (246 million) in 2007 rising to 7.3% (380 million) in 2025 worldwide.1–5 In this article, the authors consider the significance of the GLP-1 path-way in the management of T2DM, and some of the advantages of incretin-based therapy. Copyright © 2008 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"9 3","pages":"18-24"},"PeriodicalIF":0.0000,"publicationDate":"2009-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.39","citationCount":"3","resultStr":"{\"title\":\"Management of type 2 diabetes: the GLP-1 pathway\",\"authors\":\"Abd A Tahrani MMedSci, MD, MRCP, Milan K Piya MRCP, Anthony H Barnett MD, FRCP\",\"doi\":\"10.1002/fps.39\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Type 2 diabetes mellitus (T2DM) is a major challenge to healthcare systems around the world, with an estimated prevalence of 6% (246 million) in 2007 rising to 7.3% (380 million) in 2025 worldwide.1–5 In this article, the authors consider the significance of the GLP-1 path-way in the management of T2DM, and some of the advantages of incretin-based therapy. Copyright © 2008 John Wiley & Sons, Ltd.</p>\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"9 3\",\"pages\":\"18-24\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-01-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.39\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.39\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.39","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 3

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Management of type 2 diabetes: the GLP-1 pathway

Type 2 diabetes mellitus (T2DM) is a major challenge to healthcare systems around the world, with an estimated prevalence of 6% (246 million) in 2007 rising to 7.3% (380 million) in 2025 worldwide.1–5 In this article, the authors consider the significance of the GLP-1 path-way in the management of T2DM, and some of the advantages of incretin-based therapy. Copyright © 2008 John Wiley & Sons, Ltd.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Prescriber

自引率

0.00%

发文量